Sunesis Pharma Loss Narrows in Q4, Widens in 2012

Sunesis Pharmaceuticals  (NASDAQ: SNSS  ) has reported its Q4 and 2012 results.  For the quarter, revenue was just under $2 million. Comprehensive net loss narrowed to $4 million ($0.20 per diluted share) from Q4 2011's red figure of $8.7 million ($0.19). The company did not report any revenue for the latter period.

Analysts had expected revenue of $400,000 and a per-share loss of $0.19 for the most recent quarter.

For the full year, top line was $3.8 million, notably lower than the 2011 figure of $5 million. Comprehensive net loss widened considerably, landing at almost $44 million ($0.91 per diluted share) for the year against 2011's shortfall of $20 million ($0.43).


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2311699, ~/Articles/ArticleHandler.aspx, 9/24/2014 12:40:27 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement